The escalating global Mpox outbreak has been met with a concerning revelation. Two distinct studies have indicated that the ...
Two recent studies reveal that the efficacy of Bavarian Nordic's Mpox vaccine significantly declines within 6-12 months ...
Amid the rising global outbreak of Mpox, two separate studies have shown that the efficacy of Bavarian Nordic’s vaccine ...
Responding to rising mpox cases in Africa, the World Health Organization declared a public health emergency of international ...
In an emulated target trial, a single dose of modified vaccinia Ankara-Bavarian Nordic vaccine was moderately effective in ...
One dose of modified vaccinia Ankara-Bavarian Nordic (MVA-BN) smallpox vaccine is moderately effective in preventing mpox ...
"This study reinforces the benefit in vaccinating against mpox with MVA-BN and reaffirms that a single dose provides at least ...
With more than 200 mpox-related deaths reported globally, the EMA has approved Imvanex for adolescents aged 12-17 years.
The most frequently used mpox vaccine provides partial immunity to the disease but isn't always able to prevent severe symptoms or disease transmission. A new vaccine candidate from Moderna, mRNA-1769 ...
The FDA has approved ACAM2000 for prevention of mpox disease in individuals determined to be at high risk for mpox infection.